BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

NEWS: BDSI Completes Acquisition of ELYXYB Learn More >

Stay Connected

Stay up to date on the latest news and innovations from BDSI.

Asterisks denote required fields

BDSI values your privacy and will use means compliant with applicable laws to secure any personally identifiable information you provide to us. We, and parties acting on our behalf, will only use such information to send you requested materials and other helpful updates. By providing us with your information, you are hereby consenting to allow us and parties acting on our behalf to collect, store, and use the information for this purpose. At any time, if you wish to stop receiving any materials and updates or want to remove the provided information from our database, contact us at 919.582.9050.

Recent BDSI News

September 9, 2021

Expands Portfolio and Establishes Growth Platform in Neurology The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Commercial Launch Planned for Q1 2022 Investor Day on October 14, 2021 RALEIGH, N.C. , Sept.

Read more
September 7, 2021

RALEIGH, N.C. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, will showcase three scientific posters regarding BELBUCA ®  (buprenorphine buccal film), CIII

Read more
September 3, 2021

RALEIGH, N.C. , Sept. 03, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey , Chief Executive Officer, and

Read more
More news

Upcoming Events

There are no events to display

Stay Connected

Stay up to date on the latest news

Get started now
September 28, 2021BDSI $3.66/ - -2.14%
Data provided by Nasdaq. Minimum 15 minutes delayed.